Cargando…
Natalizumab in the treatment of Crohn’s disease
The pathogenesis of Crohn’s disease (CD) is multifactorial and the activation of specific pathways of immunological system is important. In particular, the adhesion molecules (integrins) mediate the selective binding between the leukocytes and the endothelial cells regulating the migration of leukoc...
Autores principales: | Guagnozzi, Danila, Caprilli, Renzo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721358/ https://www.ncbi.nlm.nih.gov/pubmed/19707360 |
Ejemplares similares
-
An evidence-based review of natalizumab therapy in the management of Crohn’s disease
por: Edula, Raja GR, et al.
Publicado: (2009) -
Natalizumab in Crohn's disease: past and future areas of applicability
por: Armuzzi, Alessandro, et al.
Publicado: (2013) -
Clinical experience of natalizumab in Crohn's disease patients in a restricted distribution program
por: Chen, Chien-Huan, et al.
Publicado: (2013) -
Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009) -
Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)